Intel stock extends gains after report of possible U.S. government stake
Investing.com -- Roche Holding AG (OTC:RHHVF) has enlisted the expertise of Morten Lammert, a senior executive from rival firm Novo Nordisk (NYSE:NVO) A/S, as they gear up to break into the highly competitive obesity drug market, according to Bloomberg News.
Lammert is set to take up his new role as the global therapeutic area head for cardiovascular, renal and metabolism at Roche on June 1, according to a company spokesperson. This position, primarily focused on the commercial market rather than research and development, is a newly created role within the Swiss pharmaceutical company.
This strategic hire comes at a time when Roche is keen to expedite the development of its experimental obesity drugs. These drugs, which have so far shown mixed results in preliminary studies, are being pushed towards the vital final phase of clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.